Miofilin (Aminophylline)

• Miofilin is a bronchodilator that acts on the respiratory tract to relieve airway constriction in several chronic and acute conditions.
• Asthma: improves airflow by relaxing bronchial smooth muscle during acute attacks.
• COPD: reduces bronchospasm and enhances ventilation in chronic obstructive disease.
• Acute bronchospasm: provides rapid relief of sudden airway narrowing in emergency settings.

• Aminophylline exerts its bronchodilatory effect by non‑selectively inhibiting phosphodiesterase enzymes, which raises intracellular cyclic AMP levels, and by antagonizing adenosine receptors. The combined actions lead to smooth‑muscle relaxation in the airways and decreased bronchial hyper‑responsiveness.

Aminophylline may cause a range of adverse reactions, from mild to severe, depending on plasma concentration and patient susceptibility.

Common Side Effects

• Nausea or vomiting: gastrointestinal upset occurring shortly after infusion.
• Headache: mild to moderate discomfort often reported during therapy.
• Tremor: fine muscle shaking, especially in the hands.
• Palpitations: sensation of rapid or irregular heartbeat.
• Insomnia: difficulty sleeping after dosing.

Serious or Rare Side Effects

• Cardiac arrhythmias: potentially life‑threatening irregular heart rhythms.
• Seizures: central nervous system excitation leading to convulsions.
• Hypotension: sudden drop in blood pressure, especially with rapid infusion.
• Severe allergic reactions: rash, bronchospasm, or anaphylaxis.
• Metabolic disturbances: hypokalemia or hyperglycemia.

• Before using Miofilin, clinicians should consider several safety measures.
• Assess cardiac status: avoid in patients with uncontrolled arrhythmias or recent myocardial infarction.
• Monitor plasma levels: therapeutic drug monitoring helps prevent toxicity.
• Evaluate renal and hepatic function: dose adjustments may be needed in impairment.
• Avoid concomitant theophylline: combined use can increase toxicity risk.
• Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Miofilin can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Macrolide antibiotics (e.g., erythromycin): may increase aminophylline plasma concentrations.
• Fluoroquinolones (e.g., ciprofloxacin): potentiate toxicity by inhibiting metabolism.

Moderate Interactions (Monitor Closely)

• Beta‑agonists (e.g., albuterol): additive bronchodilator effect may increase heart rate.
• Diuretics (e.g., furosemide): can exacerbate hypokalemia.
• Anticoagulants (e.g., warfarin): may require INR monitoring due to altered plasma protein binding.